Sign Up Today and Learn More About DNAnexus Stock
Invest in or calculate the value of your shares in DNAnexus or other pre-IPO companies through EquityZen's platform.
DNAnexus Stock (DNAN)
DNAnexus combines expertise in cloud computing and bioinformatics to create a global network for genomic medicine.
About DNAnexus Stock
Founded
2009
Headquarters
Mountain View, CA, US
Total Funding
173M
Industries
Software, Artificial Intelligence, Financial Services
DNAnexus Press Mentions
Stay in the know about the latest news on DNAnexus
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
biospace • Jun 21, 2025
Artificial Intelligence in Genomics: Revolutionizing Healthcare Through Data-Driven Insights
pharmiweb • Jun 21, 2025
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
marketscreener • Jun 21, 2025
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
businesswire • Jun 21, 2025
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
morningstar • Jun 21, 2025
Investors in DNAnexus
Discover investors in DNAnexus stock and explore their portfolio companies
DNAnexus Management
Leadership team at DNAnexus
CEO
Richard Daly
CTO
Balaji Venkateswaran
Join now and verify your accreditation status to gain access to:
- DNAnexus Current Valuation
- DNAnexus Stock Price
- DNAnexus Management
- Available deals in DNAnexus and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- DNAnexus Cap Table and Funding History by Share Class and Liquidity Preferences
- DNAnexus Revenue and Financials
- DNAnexus Highlights
- DNAnexus Business Model
- DNAnexus Risk Factors
- DNAnexus Research Report from SACRA Research
Trading DNAnexus Stock
How to invest in DNAnexus stock?
Accredited investors can buy pre-IPO stock in companies like DNAnexus through EquityZen funds. These investments are made available by existing DNAnexus shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell DNAnexus stock?
Shareholders can sell their DNAnexus stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
